News Search Results
Aug 27, 2025, 17:31 ET Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight
while aggressive lymphomas demand intensive chemotherapy protocols often supplemented with prophylactic measures to prevent central nervous system (CNS) involvement. The emphasis on multidisciplinary care and supportive therapies to mitigate side effects is further enhancing patient outcomes and influencing
More news about: DelveInsight Business Research, LLP
Aug 27, 2025, 10:40 ET Harbour BioMed Reports 2025 Interim Results
for central nervous system (CNS) disorders, including bispecific antibodies and other "Antibody-Plus (Ab+)" therapies. The pipeline in this area is currently under development, with the goal of creating more complex molecules to address the treatment challenges of CNS disorders, including neurodegenerative
More news about: Harbour BioMed
Aug 27, 2025, 10:20 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 27, 2025, 07:00 ET Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders. The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support
More news about: Leal Therapeutics
Aug 26, 2025, 10:01 ET Neurology Devices Market Size to Reach US$ 43.28 Billion by 2033 - Exclusive Report by DataM Intelligence
sophisticated healthcare infrastructure in the U.S. and Canada. The region benefits from a large patient base with CNS disorders, including Alzheimer's, which affects over 5 million Americans, with projections estimating 16 million by 2050, according to the Alzheimer's
More news about: DataM Intelligence 4 Market Research LLP
Aug 25, 2025, 13:04 ET Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research
provides precise detection and monitoring of chronic inflammation, a central driver of aging and multiple age-related diseases.NULISAseq CNS Disease Panel 120 – enables early detection and monitoring of key biomarkers involved in neurodegenerative and neurological disorders, aiming to
More news about: Human Longevity, Inc.
Aug 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 21, 2025, 11:20 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 19, 2025, 13:05 ET Ategenos Emerges from Stealth to Debut First-Ever SmartPatch Platform Transforming the Economics of Medication Non-Adherence
populationsAtegenos is advancing a proprietary drug pipeline through the FDA's 505(b)(2) regulatory pathway across behavioral health, cardiovascular, CNS, and oncology indications. At the same time, the company is exploring external development partnerships with pharmaceutical manufacturers in three key
More news about: Ategenos Pharmaceuticals Inc.
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Aug 18, 2025, 09:00 ET Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
drugs, and secured results that improved motor function in damaged animals. This is evaluated as presenting a practical solution to the development of CNS (central nervous system) targeted therapeutics, which has been difficult to achieve with existing drug delivery technologies. Dx&Vx and Avixgen
More news about: Dx&Vx
Aug 16, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 15, 2025, 07:00 ET Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
identified and characterized by Dr. Yichang Jia's group at Tsinghua University, upon delivery to the central nervous system (CNS), particularly motor neurons. This global Phase I/IIa trial will evaluate the safety and potential efficacy of SNUG01 and identify dosage for further
More news about: SineuGene Therapeutics
Aug 14, 2025, 09:04 ET SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 14, 2025, 07:00 ET Corero Network Security Grants Exclusivity in Brazil to Forte Technology as Part of Regional Expansion
Corero Network Security, (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced an exclusive channel-reseller
More news about: Corero Network Security
Aug 14, 2025, 07:00 ET Corero Network Security Concede Exclusividade No Brasil À Forte Technology Como Parte De Sua Expansão Regional
LONDRES, Reino Unido, 14 de agosto de 2025 /PRNewswire/ -- A Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconhecida em proteção contra ataques DDoS e disponibilidade adaptável de serviços em tempo real, anunciou hoje um acordo exclusivo
More news about: Corero Network Security
Aug 13, 2025, 13:06 ET Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Aug 13, 2025, 08:00 ET Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
Apertura's human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs. A third venture-backed biotechnology company has entered into an Option Agreement with Apertura for multiple CNS indications.
More news about: Apertura Gene Therapy
Aug 13, 2025, 04:12 ET FPT, 베트남-한국 반도체 및 고급 인력 양성 분야 협력 강화
산업 수요와 국제 기준에 부합하는 프로그램을 운영하고 있다. 베트남-한국 기술 협력 강화 2016년에 한국에 진출한 FPT는 한국과 베트남에서 2천여 명의 직원을 고용해 Lg전자, LG CNS, 신한은행, 대구은행, 신세계아이앤씨 등 주요 고객사를 지원하고 있다. 가트너가 선정한 한국 내 200대 기술 기업(2020–2021년)에도 포함된 FPT는 한국에 진출한 베트남 기업 중 매출과 인력 규모에서 1위 기업이다. FPT 소개
More news about: FPT Corporation
Aug 12, 2025, 08:00 ET CRC Becomes Accredited Medidata Rave® EDC Partner
research organization, specializing exclusively in CNS disorders, including neurology, psychiatry, and analgesia. Combining innovative technology, deep scientific expertise, and personalized concierge support, CRC partners with sponsors, specialized sites, and CNS experts to deliver high-quality, efficient clinical
More news about: Cognitive Research Corporation
Aug 11, 2025, 16:17 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for July 2025
YORK, Aug. 11, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of July 31, 2025,
More news about: Cohen & Steers, Inc.
Aug 11, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 08, 2025, 16:05 ET Cohen & Steers Announces Changes to Realty Indexes
YORK, Aug. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Realty Majors Portfolio Index (RMP) and Global Realty Majors Portfolio Index (GRM), effective as of the close
More news about: Cohen & Steers, Inc.
Aug 08, 2025, 10:20 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP